Status:
UNKNOWN
RaGuS Trial by Postoperative Patients
Lead Sponsor:
Bürgerspital Solothurn
Conditions:
Vasoplegic Syndrome
Sirs Due to Noninfectious Process Without Organ Dysfunction
Eligibility:
All Genders
18-99 years
Phase:
PHASE4
Brief Summary
Vasoplegic syndrome is characterized clinically by reduced systemic vascular resistance and normal or increased cardiac output. It is principally observed in cardiovascular and orthopedic intervention...
Detailed Description
Midodrine is an alpha 1 receptor agonist used usually in cases of hypotension helping to increase blood pressure. The main indication is orthostatic hypotension but there are other clinical conditions...
Eligibility Criteria
Inclusion
- Over 18 years of age
- Need of vasoactive drugs after three hours from arrival and adequate volume recovery.
Exclusion
- Signs of infection (anamnesis or pro-calcitonin \> 0.2 with leukocytosis, CRP and/or fever)
- Serum lactate \> 2mmol/l
- Mechanical ventilation
- Therapeutic restrictions or comfort measures at arrival
- "de novo" or acute on chronic heart failure (Reduction of known ejection fraction for more than 20 percent, signs of acute lung edema)
- Pregnant
- Patients with digoxin treatment or history of glaucoma.
- History of midodrine allergy, pheochromocytoma, thyrotoxicosis, tachyarrhythmias or ventricular fibrillation.
Key Trial Info
Start Date :
September 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 14 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04440085
Start Date
September 14 2020
End Date
September 14 2021
Last Update
June 19 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.